Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D8UM
|
|||
| Drug Name |
Afabicin
|
|||
| Synonyms |
UNII-DMM8663H2R; DMM8663H2R; 1518800-35-5; Afabicin [INN]; SCHEMBL15479062; SCHEMBL16262317; (6-((1E)-3-(Methyl((3-methyl-1-benzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl dihydrogen phosphate; 2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-8-((phosphonooxy)methyl)-1,8-naphthyridin-3-yl)-, (2E)-
Click to Show/Hide
|
|||
| Indication | Acute bacterial skin infection [ICD-11: 1C41] | Phase 2 | [1] | |
| Company |
Debiopharm Lausanne, Switzerland
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H24N3O7P
|
|||
| Canonical SMILES |
CC1=C(OC2=CC=CC=C12)CN(C)C(=O)C=CC3=CC4=C(N=C3)N(C(=O)CC4)COP(=O)(O)O
|
|||
| InChI |
1S/C23H24N3O7P/c1-15-18-5-3-4-6-19(18)33-20(15)13-25(2)21(27)9-7-16-11-17-8-10-22(28)26(23(17)24-12-16)14-32-34(29,30)31/h3-7,9,11-12H,8,10,13-14H2,1-2H3,(H2,29,30,31)/b9-7+
|
|||
| InChIKey |
HFYMDQMXVPJNTH-VQHVLOKHSA-N
|
|||
| CAS Number |
CAS 1518800-35-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Enoyl ACP reductase (Stap-coc fabI) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Fatty acid biosynthesis | |||
| Biotin metabolism | ||||
| Metabolic pathways | ||||
| Fatty acid metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.